KOSDAQBiotech & Pharma086890

ISU Abxis

₩3,155▼ 0.79%2026-11-18 close
Market Cap
₩128.6B
Turnover
₩57,339,708
Volume
20K
Shares out.
40.8M
PER
—
PBR
1.1×
EPS
-₩425
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit swing and Q3 loss keep earnings volatility central

ISU Abxis' quarterly results swing with overseas shipment timing and licensing royalties, and Q3 2026 returned to an operating loss of KRW 6.31 billion.

  1. 1

    Revenue of KRW 60.3 billion in 2024 was the largest year in 2022 to 2025, but fell to KRW 56.7 billion in 2025 (down 6.0% year on year) and operating profit dropped to KRW 1.63 billion (down 87.8%).

  2. 2

    Operating profit turned positive at KRW 479 million in Q2 2026, but Q3 posted an operating loss of KRW 6.31 billion as overseas shipments were deferred and inventory losses from Fabagal trial production were recognized.

  3. 3

    The cumulative net loss attributable to controlling shareholders over the last four quarters totals KRW 16.5 billion, and the Q3 2026 loss attributable to controlling shareholders was KRW 8.62 billion.

  4. 4

    The debt-to-equity ratio fell from 113.1% in 2022 to 38.8% in 2025, and operating cash flow in 2025 was KRW 11 billion.

  5. 5

    Strengths include the expansion of overseas supply markets and technology revenue, while weaknesses include large swings in quarterly sales and heavy R&D spending.

02

Business structure

ISU Abxis is an antibody-based biopharmaceutical company founded in 2001 that runs rare disease therapy sales alongside antibody drug research. Its commercial products include Abcertin, Fabagal and Clotinab, and its core activities are pharmaceutical manufacturing, import/export and sales.

Revenue is weighted toward overseas supply. After Abcertin received a Peruvian product approval in November 2022, the company signed supply contracts in Algeria and Iran, and in December 2024 it signed an exclusive licensing and supply agreement with Tabuk in Saudi Arabia.

Fabagal began a supply contract in Taiwan in March 2024 and started exports to Peru in June 2026. Revenue includes product sales as well as royalties and technology revenue from licensing deals, and the company said new royalties from technology exports began flowing in Q1 2026.

Q3 2026 results also included technology revenue from ISU106 in Russia.

The pipeline runs from the June 2024 licensing of the anticancer antibody ISU104 (barecetamab), through the January 2022 Russian licensing of the immuno-oncology drug ISU106, to the Russian product approval of the Soliris biosimilar ISU305 in December 2025.

Because country-by-country supply contracts set the unit of revenue, shipment timing in individual markets feeds directly into quarterly results. The largest shareholder is ISU Chemical, with a 33.05% stake as of July 2025.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩15.7B₩600M3.6%
2025Q4₩10.9B-₩7.8B−71.8%
2026Q1₩9.5B-₩3.4B−36.4%
2026Q2₩14.9B₩500M3.2%
2026Q3₩9.4B-₩6.3B−67.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩41.2B-₩16B-₩7.2B−38.9%−11.3%113.1%
2023₩54.3B₩3.9B₩3.6B7.2%4.7%167.8%
2024₩60.3B₩13.4B₩14.7B22.2%14.6%58.9%
2025₩56.7B₩1.6B-₩10.7B2.9%−9.3%38.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a reported annual basis, revenue rose from KRW 41.2 billion in 2022 to KRW 54.3 billion in 2023 (up 31.9% year on year) and KRW 60.3 billion in 2024 (up 11.0%), then fell to KRW 56.7 billion in 2025 (down 6.0%). Of the 2022 to 2025 years, 2024 was the largest and 2022 the smallest.

Operating results moved from an operating loss of KRW 16 billion in 2022 to operating profit of KRW 3.89 billion in 2023, which marked the turn to profit, and then to KRW 13.4 billion in 2024 (up 244.9%). The operating margin went from -38.9% in 2022 to 7.2% in 2023 and 22.2% in 2024.

In 2025 operating profit fell to KRW 1.63 billion (down 87.8%), pushing the margin down to 2.9%. Net profit attributable to controlling shareholders was KRW 3.61 billion in 2023 and KRW 14.7 billion in 2024, but in 2025 it turned into a loss of KRW 10.7 billion.

Operating cash flow in the same year was KRW 11 billion, up from KRW 2.54 billion in 2024. The quarterly pattern is more volatile.

After Q3 2025 revenue of KRW 15.7 billion and operating profit of KRW 562 million, Q4 2025 revenue fell to KRW 10.9 billion (down 30.6% from the prior quarter) and the company posted an operating loss of KRW 7.85 billion. Q1 2026 revenue was KRW 9.45 billion with an operating loss of KRW 3.44 billion.

Q2 2026 revenue rose to KRW 14.9 billion (up 57.9% from the prior quarter) and operating profit was KRW 479 million, a return to profit. Q3 2026 revenue was KRW 9.36 billion, down 40.5% from a year earlier, and the operating loss widened to KRW 6.31 billion.

In its preliminary disclosure on November 5, 2026, the company attributed the Q3 revenue decline to adjusted shipment schedules for some overseas volumes, and the wider operating loss to one-off costs, including inventory disposal and valuation losses from trial production for Fabagal process verification.

The company said deferred revenue will be reflected in Q4. The cumulative net loss attributable to controlling shareholders over the last four quarters totals KRW 16.5 billion. The company also said R&D spending equaled 41.2% of revenue in Q1 2026.

05

Industry analysis

The rare disease therapy market involves small patient populations offset by high drug prices and country-by-country supply contracts. ISU Abxis recognizes revenue according to supply and shipment timing in each country, and the company itself says overseas pharmaceutical operations create such timing gaps.

For that reason it argues the business should be read on an annual basis rather than by single quarter. On the licensing side, ISU Abxis hands antibody drugs to overseas partners and receives royalties.

Compared with technology-export names such as LigaChem Biosciences or ABL Bio, ISU Abxis rests its results on overseas sales of commercial products. Licensing deals arrive irregularly in size and timing, which makes them a source of quarterly volatility.

The Soliris biosimilar ISU305 has received a Russian product approval, and its contribution to earnings will depend on the launch timing and supply volume after approval.

Across the pharmaceutical and health supplement sector of 139 listed companies, ISU Abxis ranks 99th on revenue and 70th on operating margin on an annual basis, so both scale and profitability sit well below the sector average.

06

Outlook

When it released preliminary Q3 2026 results, the company said the business should be read over the full year rather than one quarter, and that if deferred revenue is recognized in Q4, the full-year operating picture will not change much.

It also said it will keep widening overseas markets to strengthen a stable revenue base and focus R&D resources on new pipeline programs. At the Q1 2026 release, the company said delayed export volumes would ship in sequence from Q2, and Q2 operating profit then turned positive at KRW 479 million.

At the same time the company said major new drug data are due to be disclosed in the second half of 2026, and it described a two-track strategy built on multi-specific antibodies and a platform approach. It said R&D is concentrated on assets with high success odds and promising licensing prospects.

The start of Fabagal exports to Peru in June 2026 and the research collaboration on rare disease therapies signed in February 2026 are already-confirmed progress.

The variables that will decide future earnings are the results of the second-half drug data, whether deferred revenue shows up in Q4, and whether inventory losses and R&D spending decline as revenue grows.

07

Valuation

PER
—
PBR
1.1×
ROE
-14.4%
EPS
-₩425
BPS
₩2,884
Dividend per share
₩0

The stock currently sits in a range where the last four quarters show net losses, so PER cannot be calculated. On the balance sheet, total equity at the end of 2025 was KRW 114.5 billion against total liabilities of KRW 44.4 billion, a debt-to-equity ratio of 38.8%.

The shares trade at a modest premium to net asset value and below the sector average price-to-book ratio. The company pays no dividend, so its dividend yield sits far below the sector average.

On an earnings basis, 2024, when net profit attributable to controlling shareholders reached KRW 14.7 billion, and the current four-quarter loss stretch look very different.

Profit grew from 2023 through 2024 and then turned into a loss in 2025, so whether earnings recover is the starting point for any multiple calculation. If licensing deals are recognized in results, earnings-based multiples would be recalculated.

The valuation discussion therefore depends on annual accumulation of overseas supply results and the size of licensing royalties.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Wider overseas supply footprint

Fabagal started exports to Peru in June 2026, and Abcertin signed an exclusive licensing and supply agreement with Tabuk in Saudi Arabia. Revenue of KRW 60.3 billion in 2024 was the largest year in the 2022 to 2025 span. The company said it will keep expanding overseas markets to strengthen a stable revenue base.

Licensing royalties starting to flow

The company said new royalties from technology exports began flowing in Q1 2026. Operating profit turned positive at KRW 479 million in Q2 2026.

Improved balance sheet

The debt-to-equity ratio fell from 113.1% in 2022 to 38.8% in 2025. Against total equity of KRW 114.5 billion at the end of 2025, total liabilities were KRW 44.4 billion. Operating cash flow improved from -KRW 402 million in 2022 to KRW 2.54 billion in 2024 and KRW 11 billion in 2025.

09

Bear factors

Large swings in quarterly results

After an operating loss of KRW 7.85 billion in Q4 2025, the company returned to profit in Q2 2026 but posted an operating loss of KRW 6.31 billion in Q3. Q3 revenue of KRW 9.36 billion fell 40.5% from a year earlier.

The cumulative net loss attributable to controlling shareholders over the last four quarters totals KRW 16.5 billion.

Profitability deterioration in 2025

Operating profit fell 87.8% to KRW 1.63 billion in 2025, pulling the operating margin down to 2.9%. Net profit attributable to controlling shareholders turned into a loss of KRW 10.7 billion from KRW 14.7 billion. Revenue also fell 6.0% to KRW 56.7 billion in 2025.

R&D burden and pipeline uncertainty

The company said R&D spending equaled 41.2% of revenue in Q1 2026. Major new drug data are scheduled for the second half of 2026, but the results are not yet known. The direction of earnings could shift depending on licensing outcomes and pipeline results.

10

Risk factors

Overseas shipment and export timing risk

Overseas pharmaceutical sales recognize revenue according to country-level supply and shipment schedules. In Q3 2026 some overseas shipments were rescheduled, and revenue fell 40.5% from a year earlier. How much deferred revenue lands in Q4 will shape the full-year picture.

Production and inventory risk

Q3 2026 operating losses included one-off costs such as inventory losses from trial production used to verify the Fabagal process. The company says such inventory disposal and valuation losses are separate from normal selling costs. Whether similar costs recur will be central to judging the cost structure.

Pipeline and licensing uncertainty

Technology revenue from the ISU104 licensing and ISU106 in Russia is already flowing into results. Clinical outcomes for new pipeline assets and whether further licensing deals close remain undetermined.

The largest shareholder, ISU Chemical, held 33.05% as of July 2025, a concentrated ownership structure that should be read alongside the float.

11

What to watch next

  1. By late December 2026 (per company second-half schedule)

    Results of major new drug data. This is the first public point for judging pipeline value and the likelihood of further licensing deals.

  2. February 2027 (typical timing of annual preliminary results)

    Q4 and full-year 2026 preliminary results. This is where to check whether deferred revenue appears in Q4 and whether Fabagal inventory losses recur.

  3. By March 31, 2027

    Filing of the 2026 annual report. Full-year operating margin and net profit attributable to controlling shareholders are finalized on this regulatory basis.

  4. May 2027 (typical timing of Q1 preliminary results)

    Q1 2027 revenue and technology revenue size. This shows whether overseas export volumes are stable and royalty inflows continue.

12

Overall view

ISU Abxis recorded revenue of KRW 60.3 billion and operating profit of KRW 13.4 billion in 2024, supported by overseas supply of rare disease therapies and licensing royalties. In 2025 revenue fell to KRW 56.7 billion and the company swung to a net loss attributable to controlling shareholders of KRW 10.7 billion.

In 2026 a Q2 operating profit turn was followed by a Q3 operating loss of KRW 6.31 billion, and the company attributed part of the Q3 loss to one-off factors such as deferred overseas shipments and Fabagal inventory losses.

The balance sheet improved, with the debt-to-equity ratio falling from 113.1% in 2022 to 38.8% in 2025. However, the cumulative net loss attributable to controlling shareholders over the last four quarters totals KRW 16.5 billion, and R&D spending is heavy relative to revenue, so earnings capacity is not yet stable.

Strengths include the widening overseas supply footprint and Russian technology revenue, while weaknesses include quarterly revenue swings and uncertainty around pipeline outcomes.

The next checkpoints are the results of second-half 2026 drug data, whether deferred revenue appears in Q4 2026 preliminary results, and full-year operating margin in the 2026 annual report. This report does not present an investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. alphasquare.co.kr
  2. newspim.com
  3. newspim.com
  4. medipharmhealth.co.kr
  5. vegannews.co.kr
  6. saramin.co.kr
  7. goinsider.kr
  8. isuabxis.career.greetinghr.com
  9. hankyung.com
  10. judal.co.kr
  11. pharm.edaily.co.kr
  12. littlebproject.com
  13. judal.co.kr
  14. eduinfom.com
  15. judal.co.kr
  16. judal.co.kr
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis